Acceleron Pharma, Inc (XLRN)

Trade XLRN now with
9/9/2019 7:10:36 AM Acceleron Gets FDA Orphan Drug Designation For Sotatercept In Pulmonary Arterial Hypertension
8/5/2019 4:19:40 PM Acceleron Pharma Q2 Loss/share $0.34 Vs. Loss $0.63 Year Ago
6/26/2019 7:48:48 AM Acceleron Completes Target Enrollment In The PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension
4/5/2019 9:38:31 AM Celgene And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To FDA
1/16/2019 7:03:44 AM Acceleron Pharma Prices Public Offering Of 5.35 Mln Shares At $43/Shr For Gross Proceeds Of $230.0 Mln
1/14/2019 4:06:45 PM Acceleron Announces Proposed Public Offering Of Common Stock
12/2/2018 5:40:17 PM Celgene And Acceleron Pharma Announce Results Of Phase 3 MEDALIST Trial Evaluating Luspatercept In Patients With MDS
11/28/2018 7:10:00 AM Acceleron Receives FDA Fast Track Designation For ACE-083 In Charcot-Marie-Tooth Disease
7/23/2018 7:03:55 AM Acceleron Announces Positive Preliminary Results From Part 1 Of The ACE-083 Phase 2 Trial
7/12/2018 7:04:39 AM Acceleron Pharma Says FDA Granted Orphan Drug Designation For ACE-083
7/5/2018 4:31:51 PM Acceleron Appoints Robert Zeldin As Chief Medical Officer